Morrow Phuong Khanh 4
4 · CRISPR Therapeutics AG · Filed Mar 14, 2023
Insider Transaction Report
Form 4
Morrow Phuong Khanh
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-03-10+44,620→ 44,620 totalExercise: $43.22Exp: 2033-03-10→ Common Shares (44,620 underlying) - Award
Restricted Stock Units
2023-03-10+22,000→ 22,000 total→ Common Shares (22,000 underlying)
Footnotes (3)
- [F1]This option was granted on March 10, 2023 with respect to 44,620 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2023.
- [F2]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F3]This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.